Samsung C&T Says Samsung Biologics Delays PolyPeptide Acquisition to Dec. 31, 2026

Samsung C&T corrected Samsung Biologics' planned PolyPeptide acquisition settlement date to Dec. 31, 2026, from Nov. 30, 2026. The planned cash acquisition covers 33,016,411 shares for KRW 2.71 trillion, aimed at strengthening its peptide CDMO business. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Samsung C&T Corporation published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261016800879), on October 16, 2026, and is solely responsible for the information contained therein. (C)